Related Experiment Video

Updated: Jan 22, 2026

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells
09:02

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells

Published on: June 5, 2020

7.9K

Non-invasive biomarkers for chronic hepatitis B virus infection management

Caroline Charre1, Massimo Levrero2, Fabien Zoulim2

  • 1INSERM U1052-Cancer Research Center of Lyon (CRCL), 69008, Lyon, France; University of Lyon, University Claude Bernard Lyon 1 (UCBL1), Lyon, France; Department of Virology, Croix Rousse Hospital, Hospices Civils de Lyon, Lyon, France.

Antiviral Research
|July 10, 2019
PubMed

Insights

New biomarkers are being developed to monitor chronic hepatitis B virus (HBV) infection. These non-invasive markers can assess covalently closed circular DNA (cccDNA) levels and activity, aiding patient classification and drug development.

Area of Science:

  • Hepatology
  • Virology
  • Biomarker Discovery

Background:

  • Chronic hepatitis B virus (HBV) infection affects over 250 million people globally, leading to severe liver diseases like cirrhosis and hepatocellular carcinoma.
  • Current antiviral therapies fail to eliminate HBV covalently closed circular DNA (cccDNA) within hepatocytes, hindering complete recovery.
  • Existing biomarkers lack accuracy in reflecting intrahepatic cccDNA levels and transcriptional activity, complicating patient management.

Purpose of the Study:

  • To review emerging non-invasive biomarkers for assessing intrahepatic HBV cccDNA abundance and transcriptional activity.
  • To discuss the relevance of these biomarkers in improving patient classification and understanding disease natural history.
  • To highlight their utility in evaluating novel antiviral compounds and defining new virological endpoints.

Main Methods:

  • Review of current literature on HBV biomarkers.
  • Discussion of novel serum and RNA-based markers.
  • Analysis of biomarker relevance for clinical monitoring and drug development.

Main Results:

  • Serum HB core-related antigen and circulating HBV RNAs show promise as surrogate biomarkers.
  • These novel markers may provide a more accurate reflection of intrahepatic cccDNA and its activity.
  • Potential for improved patient stratification and assessment of antiviral treatment efficacy.

Conclusions:

  • Non-invasive biomarkers are crucial for better management of chronic HBV infection.
  • Emerging biomarkers can enhance patient classification and guide the development of new therapies.
  • Accurate assessment of cccDNA is key to achieving sustained virological response and potential cure.

Keywords:
Antiviral therapyChronic hepatitis BHBVSerum markercccDNA

More Related Videos

"Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection10:25

"Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection

Published on: February 19, 2019

12.1K
Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle09:35

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

Published on: February 1, 2017

13.9K

Related Concept Videos

Chronic Obstructive Pulmonary Disease-V: Management01:29

Chronic Obstructive Pulmonary Disease-V: Management

Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
3.1K
Chronic Obstructive Pulmonary Disease-V: Nursing Management01:30

Chronic Obstructive Pulmonary Disease-V: Nursing Management

Nursing management of Chronic Obstructive Pulmonary Disease (COPD) is crucial for providing thorough care and support to patients. Nurses play an integral role in this process through detailed assessment, careful planning, targeted interventions, and ongoing evaluation. Here's an overview of the critical steps in nursing management for COPD.
Assessment
5.1K
Chronic Kidney Disease IV: Nursing Management01:18

Chronic Kidney Disease IV: Nursing Management

Nursing management is essential for preventing complications, maintaining stability, and improving patients' quality of life in chronic kidney disease (CKD). By using a structured approach, nurses help slow CKD progression and support effective patient care​.1. Comprehensive patient assessmentEffective management begins with nurses reviewing the patient’s medical history, and identifying key risk factors like diabetes, hypertension, and nephrotoxic drug use. Nurses assess signs of...
331
Urinary Tract Infection IV: Nursing Management01:17

Urinary Tract Infection IV: Nursing Management

In managing urinary tract infections (UTIs) in nursing, a comprehensive assessment is essential. Begin by gathering subjective data, such as the patient’s complaints of dysuria (painful urination), urinary frequency, urgency, suprapubic pain, and any lower abdominal discomfort. This information can be complemented by questions regarding previous UTIs, sexual activity, and personal hygiene practices, which can provide insight into risk factors. Objective assessment should focus on signs...
446
What are Viruses?00:50

What are Viruses?

Overview
127.8K
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
261